Dibavally Plus 50/1000 Mg 28 Tablets

Dibavally Plus 50/1000 Mg 28 Tablets

Description:

Dibavally Plus 50/1000 mg 28 tablets is an oral prescription antidiabetic medicine used for the management of type 2 diabetes mellitus in adults. It combines two active ingredients, vildagliptin (a dpp-4 inhibitor) and metformin hydrochloride (a biguanide), to help control high blood sugar levels when diet and exercise alone, or metformin alone, are not sufficient. This dual-action tablet improves insulin secretion after meals, reduces glucose production in the liver, and enhances insulin sensitivity, supporting better long-term blood glucose control and helping reduce the risk of diabetes-related complications such as cardiovascular disease, kidney damage, and nerve damage.

Indications:

• Management of type 2 diabetes mellitus in adults, particularly when blood glucose is not adequately controlled with metformin alone, diet, and exercise.
• Helps reduce elevated fasting and postprandial (after-meal) blood glucose levels.
• May be used as part of combination therapy with other antidiabetic agents as prescribed by a physician.
• Aims to reduce the risk of long-term complications associated with poorly controlled type 2 diabetes, such as cardiovascular events, neuropathy, nephropathy, and retinopathy, when used as part of a comprehensive treatment plan.

Active Ingredients / Key Components:

• Vildagliptin – 50 mg per tablet (dpp-4 inhibitor; enhances glucose-dependent insulin secretion and reduces glucagon levels).
• Metformin hydrochloride – 1000 mg per tablet (biguanide; decreases hepatic glucose production and improves peripheral insulin sensitivity).
• Other excipients: Full list of inactive ingredients (excipients, coating agents, stabilizers) is not available in the provided information. Please refer to the official package leaflet for the complete composition.

Dosage & Administration / How to Use:

• Dibavally Plus 50/1000 mg is for oral use only and should be taken exactly as prescribed by your physician.
• Typical adult dose (when prescribed): one tablet twice daily or as directed by the treating doctor. The exact dose, frequency, and duration depend on individual blood glucose control, renal function, and concomitant medications.
• Take the tablets with food, usually during or immediately after a meal, to reduce the risk of gastrointestinal side effects associated with metformin (such as nausea and stomach upset).
• Swallow the tablet whole with a glass of water. Do not crush or chew unless your doctor or pharmacist specifically advises otherwise.
• Do not change the dose, skip doses, or stop taking the medicine without consulting your healthcare provider.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose to make up for a missed tablet.
• Use in patients with kidney or liver impairment requires careful medical assessment and possible dose adjustment or avoidance. Always follow your doctor’s instructions.

Clinical Benefits:

• Provides dual mechanism blood sugar control by combining vildagliptin and metformin in a single tablet for convenient diabetes management.
• Helps lower both fasting and postprandial blood glucose levels, contributing to improved overall glycemic control (lower hba1c levels).
• Supports glucose-dependent insulin secretion and reduces excess glucagon, helping to minimize the risk of hypoglycemia compared with some other secretagogues when used as directed.
• Metformin component helps reduce hepatic glucose production and improve insulin sensitivity, which can support weight neutrality or modest weight reduction in many patients.
• Convenient fixed-dose combination may improve adherence compared to taking separate tablets of vildagliptin and metformin.
• When used as part of a comprehensive treatment plan (diet, exercise, and regular monitoring), it helps reduce the risk of long-term microvascular and macrovascular complications of type 2 diabetes.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity or allergy to vildagliptin, metformin hydrochloride, or any of the tablet’s excipients.
• Contraindicated in patients with severe renal impairment or significant reduction in kidney function, and in conditions that may affect kidney function (e.g., severe dehydration, severe infection, shock).
• Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis or lactic acidosis, with or without coma.
• Use with caution in patients with liver impairment, heart failure, history of pancreatitis, or those at risk of lactic acidosis (e.g., elderly, alcohol abuse, hypoxic states).
• Temporary discontinuation may be required before and after radiological studies involving iodinated contrast agents or major surgery; follow your doctor’s instructions.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. The safety of vildagliptin/metformin combination in pregnancy and lactation must be assessed by a specialist.
• Inform your doctor about all other medications you are taking, especially other antidiabetics, diuretics, antihypertensives, corticosteroids, or drugs that may affect kidney function or blood glucose.
• Not intended for use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Alcohol intake should be limited or avoided during treatment due to increased risk of lactic acidosis.
• Monitor blood glucose regularly as advised and attend all scheduled medical and laboratory check-ups (including kidney and liver function tests).
• Keep out of reach of children.

Side Effects:

• Common side effects may include nausea, vomiting, diarrhea, abdominal pain, loss of appetite, headache, dizziness, and mild hypoglycemia (especially when used with other antidiabetic drugs).
• Vildagliptin-containing products may rarely cause liver function abnormalities; your doctor may monitor liver enzymes periodically.
• Metformin may rarely cause lactic acidosis, a serious medical emergency characterized by rapid breathing, severe weakness, muscle pain, abdominal discomfort, feeling cold, dizziness, or slow/irregular heartbeat. Seek immediate medical attention if these symptoms occur.
• Hypersensitivity reactions such as rash, itching, or swelling of the face, lips, or throat may occur. Stop the medicine and seek urgent medical help if signs of severe allergy or difficulty breathing appear.
• Pancreatitis (inflammation of the pancreas) has been reported with dpp-4 inhibitors. Symptoms include severe, persistent abdominal pain that may radiate to the back, with or without vomiting. Stop the medicine and contact your doctor immediately if these occur.
• If any side effect persists, worsens, or if you notice any unusual symptoms, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.

Specifications:

• Product type: oral antidiabetic medicine (fixed-dose combination).
• Strength: vildagliptin 50 mg + metformin hydrochloride 1000 mg per tablet.
• Form: film-coated tablets.
• Pack size: 28 tablets per pack.
• Intended use: adult patients with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.